Usher Syndrome in the Inner Ear: Etiologies and Advances in Gene Therapy

Evan M. de Joya 1,2,†, Brett M. Colbert 1,2,3,†, Pei-Ciao Tang 1, Byron L. Lam 4, Jun Yang 5, Susan H. Blanton 1,2,‡, Derek M. Dykxhoorn 2 and Xuezhong Liu 1,2,6,*

1 Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA; edejoya@med.miami.edu (E.M.J.); bmc48@miami.edu (B.M.C.); peictang@med.miami.edu (P.-C.T.); sblanton@med.miami.edu (S.H.B.)
2 Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA; ddykxhoorn@med.miami.edu
3 Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL 33136, USA
4 Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA; blam@med.miami.edu
5 John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, UT 84132, USA; jun.yang@hsc.utah.edu
6 Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
* Correspondence: x.liu1@med.miami.edu; Tel.: +1-(305)-243-2000; Fax: +1-(305)-243-2409
† These authors contributed equally to this work.

Abstract: Hearing loss is the most common sensory disorder with ~466 million people worldwide affected, representing about 5% of the population. A substantial portion of hearing loss is genetic. Hearing loss can either be non-syndromic, if hearing loss is the only clinical manifestation, or syndromic, if the hearing loss is accompanied by a collage of other clinical manifestations. Usher syndrome is a syndromic form of genetic hearing loss that is accompanied by impaired vision associated with retinitis pigmentosa and, in many cases, vestibular dysfunction. It is the most common cause of deaf-blindness. Currently cochlear implantation or hearing aids are the only treatments for Usher-related hearing loss. However, gene therapy has shown promise in treating Usher-related retinitis pigmentosa. Here we review how the etiologies of Usher-related hearing loss make it a good candidate for gene therapy and discuss how various forms of gene therapy could be applied to Usher-related hearing loss.

Keywords: syndromic hearing loss; retinitis pigmentosa; CRISPR; antisense oligonucleotides

1. Introduction

Hearing Loss

The ear is a highly evolved sensory organ with a complex mechanotransduction pathway. As such, there is significant room for genetic changes leading to hearing loss [1]. The ear can be divided into three anatomical sections—the outer ear (from the visible pinna to the ear canal), the middle ear (from the tympanic membrane to the oval window including the smallest bones in the body), and the inner ear (the semicircular canal, vestibule, and cochlea). Hearing begins when sound is funneled into the ear canal by the pinna [2]. The waves then travel down the canal and come in contact with the tympanic membrane, also known as the ear drum. Here, sound waves are translated into mechanical vibrations and are passed down the bones of the middle ear, from the malleus to the incus to the stapes and through the oval window into the cochlea. The cochlea is a spiral-shaped structure filled with potassium-rich endolymph. Vibrations propagate through the endolymph and deflect the stereocilia of hair cells in the organ of Corti. Movements of the stereocilia result in the opening of ion channels on the hair cells, producing an action potential. Through
this process mechanical sound waves are converted into electrical impulses that travels down the vestibulocochlear nerve (CNVIII) to be processed by the brain. Failure at any one of these steps will result in hearing reduction or loss [1,3,4].

Hearing loss (HL) is the most common sensory deficit. Estimates place the prevalence of disabling hearing loss at around 466 million people worldwide representing about 5% of the population [5]. Approximately half of all cases of severe to profound hearing loss have a genetic basis [6,7]. HL is often the result of a defect in a single gene which can be inherited in an autosomal dominant, autosomal recessive, X-linked, or mitochondrial manner. Hearing loss is classified as syndromic if there are other clinical manifestations in addition to the hearing loss, and non-syndromic if hearing loss is the only symptom of the genetic variant [8–10]. Non-syndromic HL makes up eighty percent of cases of genetic hearing loss. Among the non-syndromic forms of HL, 60–75% of these are inherited in an autosomal recessive manner, 20–30% are autosomal dominant, with a small minority (~2%) resulting from X-linked or mitochondrial inheritance [11,12]. To date, there have been more than 150 genes and 6000 causative variants implicated in genetic causes of hearing loss [12–16]. The remaining ~20% of genetic hearing loss cases are syndromic.

An example of syndromic hearing loss is Usher syndrome. Usher syndrome is characterized by hearing loss, visual impairment due to retinitis pigmentosa (RP), and in some cases, vestibular dysfunction [17]. Usher syndrome is the most common cause of deaf-blindness and an important etiology underlying autosomal recessive deafness.

While some of the genes resulting in Usher syndrome have been identified for some time there has been limited progress in therapeutic options for hearing loss in these patients [18]. Supportive techniques such as hearing aids or cochlear implants are the only options for those subtypes that are amenable [19]. The advent of genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, has brought the promise of gene therapies within reach. In this review, we focus on the progress towards novel therapies for Usher syndrome and how these can be applied to Usher-related hearing loss.

2. Usher Syndrome
2.1. Classification of Usher Syndrome

Clinically, Usher syndrome is differentiated into three distinct types—Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2), and Usher syndrome type 3 (USH3). These types are differentiated by the degree of hearing impairment, age of visual problem onset, and the presence or absence of vestibular dysfunction [17,20].

Usher type 1 has the most severe manifestations and accounts for 25 to 44% of all Usher patients [21]. USH1 patients present with severe-to-profound bilateral sensorineural hearing loss (SNHL) and RP at an average age of nine years [22,23]. If hearing loss is left untreated, speech development may be interrupted [23]. Vestibular areflexia is present in all patients with USH1 and leads to balance deficits with children experiencing delayed walking and motor development [24].

Usher type 2 patients have moderate-to-severe congenital HL, which is less pronounced than the HL in USH1 [25,26]. USH2 is the most common type, accounting for more than 50% of all observed cases [21,27]. USH2 patients retain normal vestibular function and experience a later onset of RP in the second decade of life with an average age of 17 years [22,28].

Usher type 2 patients have moderate-to-severe congenital HL, which is less pronounced than the HL in USH1 [25,26]. USH2 is the most common type, accounting for more than 50% of all observed cases [21,27]. USH2 patients retain normal vestibular function and experience a later onset of RP in the second decade of life with an average age of 17 years [22,28].

Usher type 3 is the least common type, accounting for an estimated 2 to 5% of all Usher cases [27,29]. Hearing loss in USH3 progressively worsens as individuals age [30]. RP onset in USH3 is variable, but typical onset is around age 20 years [24]. USH3 patient also experience vestibular phenotypes. In all three types of Usher syndrome, hearing loss occurs before the onset of visual impairment [31]. Balance deficits in USH1 and USH3 can be aggravated further by the loss of vision due to RP [18].
2.2. Genetics of Usher Syndrome

The relatively low frequency of Usher syndrome and heterogeneity in populations makes it difficult to understand its true prevalence. Usher syndrome is a significant cause of autosomal recessive hearing loss among deaf and hard-of-hearing children. Estimates of prevalence vary by country, ranging from 3 to 6.2 per 100,000, but up to 16.7 per 100,000 in American children [29,32,33].

Within each type of Usher syndrome there are numerous subtypes associated with various genes and loci (Table 1). At least 11 causative or suspected genes have been identified, six associated with USH1, three with USH2, and two with USH3. Digenic inheritance in Usher syndrome—mutations in two Usher-related genes—has been proposed, though the existence of digenic inheritance is contradicted by recent analyses [31]. Additional loci have been mapped, such as USH1E, USH1H, USH1K, and USH2B, but the underlying gene has not been identified [34–37].

Table 1. Usher type, subtype, and associated genes.

| Type          | Subtype | Gene Involved | Protein Product | Protein Function | NSHL Classification | References |
|---------------|---------|---------------|-----------------|------------------|---------------------|------------|
| Usher Type 1  | USH1B   | MYO7A         | Myosin VIIA     | Actin-binding molecular motor | DFNB2/DFNA11 | [38–40] |
|               | USH1C   | USH1C         | Harmonin        | Scaffolding protein | DFNB18 | [41–43] |
|               | USH1D   | CDH23         | Cadherin 23     | Cell adhesion molecule (Upper tip-link) | DFNB12 | [44,45] |
|               | USH1F   | PCDH15        | Protocadherin 15 | Cell adhesion molecule (Lower tip-link) | DFNB23 | [46–48] |
|               | USH1G   | USH1G         | Sans            | Scaffolding protein | - | [49] |
|               | USH1J   | CIB2 *        | Calcium and integrin binding protein | Calcium and integrin binding protein | DFNB48 | [50–53] |
| Usher Type 2  | USH2A   | USH2A         | Usherin         | Cell adhesion molecule | - | [54,55] |
|               | USH2C   | ADGRV1 **     | Adhesion G-coupled receptor V1 | Adhesion G-coupled receptor V1 | - | [56] |
|               | USH2D   | WHRN          | Whirlin         | Scaffolding protein | DFNB31 | [57–59] |
| Usher Type 3  | USH3A   | CLRN1         | Clarin-1        | Transmembrane protein used in scaffolding and cellular trafficking | - | [60–62] |
|               | USH3B   | HARS ***      | Histidine tRNA ligase | Histidine tRNA ligase | - | [63] |

* CIB2 involvement in Usher is contested. ** Formerly GPR98 or VLGR1. *** Research on HARS in Usher is limited. NSHL = non-syndromic hearing loss; classification numbers were included if mutations also lead to NSHL.

Due to regional founder effects, Usher subtype composition varies by population. Among French Canadians in Quebec, USH1C is the major genetic USH1 subtype due to a founder mutation [64], while the R245 * founder mutation associated with USH1F was found to be a significant cause of USH1 in Ashkenazi Jewish populations [65].

USH3 is the least common of all Usher types, though it is found more frequently in Ashkenazi Jewish and Finnish populations [65–68]. In many of these cases, founder mutations account for the increased prevalence of a specific Usher syndrome type. For example, all Finnish patients with USH3A carry the same mutation Y176 * associated with USH3A [66].

2.3. Usher Protein Function

Proteins encoded by Usher genes have various roles in the development and function of the inner ear (Table 1). Usher proteins are most abundant in the stereocilia and the
synaptic regions of hair cells and guide the cohesion and development of hair bundles [27]. Myosin VIIa (USH1B), harmonin b (USH1C), and cadherin 23 (USH1D) are responsible for the cohesion of the stereocilia, the shaping of the hair bundle and cadherin 23 and protocadherin 15 are integral to the structure of the tip links [69]. The SANS protein (USH1G) is a scaffolding protein that associates with harmonin b protein [49,70]. ADGRV1 (USH2C) and usherin (USH2A) are components of ankle links, filaments connected to the base of stereocilia [55,71]. Further, WHRN (USH2D) has been observed to interact with ADGRV1 and usherin at the ankle links and co-localize with these proteins at the synaptic regions of outer hair cells in the cochlea to promote synaptic adhesion and development [72]. CLRN-1 (USH3A) is a hair bundle protein with four transmembrane domains necessary for the shape and development of the bundle and ribbon playing a role in mechano-electrical transduction [61,73,74].

3. Progress and Challenges in Gene Therapy for Usher Syndrome

3.1. Current Treatment Modalities for Usher-Related Hearing Loss

Current therapies for HL range from sound amplification to cochlear implantation (CI). The current treatment for USH1- and USH3-induced hearing loss is CI [23,75]. Hearing loss caused by USH2 is typically less severe, and the current intervention is hearing aids [76]. The existing interventions for Usher-related hearing loss are invasive and expensive, and gene therapy presents an opportunity to greatly improve outcomes through restoration of an individual’s endogenous hearing, ending the reliance on devices that do not faithfully recapitulate normal hearing [77–79]. Hearing aids are limited in providing high frequency access, which is imperative for speech understanding. With cochlear implants, while they improve audibility up to the normal range, the signal is highly degraded. These limitations for invasive and non-invasive treatments do not allow for full restoration of hearing resulting in poorer speech understanding than normal hearing peers, specifically in situations with significant background noise.

Early diagnosis and intervention in Usher syndrome are critical to improving prognosis [80]. Particularly in USH1, sign language is a decreasingly effective method of communication due to the early onset of RP and subsequent vision loss [81]. Currently, Usher syndrome is diagnosed at a mean age of 10, with USH1 diagnosed earlier than USH2 or USH3 [23]. Achieving earlier diagnosis of Usher syndrome is a requisite for the successful development and delivery of gene therapy for the inner ear.

3.2. Therapy for Usher-Related Retinitis Pigmentosa

Although gene therapy for RP caused by any etiology has shown promise, in this review we will focus on treatments for retinitis pigmentosa caused by Usher pathogenic genes. Using ClinicalTrials.gov (Search terms: Condition or Disease—“retinitis pigmentosa”, other terms—“Usher AND therapy”) relevant trials were identified. Results were screened to include only trials targeting RP associated with an Usher subtype using gene transfer, editing, or suppression therapy.

Our search identified two relevant trials (Table 2). In the SAR421869 trial, an equine infectious anemia-virus-based (EIAV) lentiviral vector expressing MYO7A was delivered via subretinal injections to patients with USH1B. The Phase I/IIA trial was terminated by the company for a review of clinical development plans and priorities after the license was returned from Sanofi to Oxford Biomedica [82]. In the QR-421a trial, an antisense oligonucleotide is being used to target a defective exon 13 in USH2A patients. The trial, currently in Phase I/II is ongoing, and results have not yet been released [83].

| Therapeutic | Usher Subtype | Gene Involved | Phase Reached | Status |
|-------------|---------------|---------------|---------------|--------|
| UshStat (SAR421869) [84] | USH1B | MYO7A | Phase I/IIA | Suspended, 2017 Terminated, 2019 |
| QR-421a [85] | USH2A | USH2A | Phase I/II | Ongoing |
3.3. Defining Gene Therapy

Gene therapy presents a promising potential treatment especially for monogenic diseases. Gene therapies include the insertion, deletion, or replacement of whole genes, or the editing of existing pathogenic sequences within the endogenous copies of the gene. For each intended effect, there are different therapeutic modalities. Gene replacement modalities utilize a vector, typically a virus, to deliver a functional copy of a defective gene. Gene editing modalities, such as the CRISPR/Cas9 system, are able to modify the DNA sequence by inducing double strand breaks and subsequent homology-directed repair using a template DNA containing the sequence of interest. This precision allows for the introduction of the specific DNA variant while leaving the remaining sequence unaltered.

3.4. Gene Therapy for the Inner Ear

The inner ear is an attractive target for gene therapy. Attempts to correct Usher-related HL thus far has mainly focused on mouse models. The only gene therapy targeting the inner ear to reach human clinical trials is CGF166, a recombinant adenovirus 5 (Ad5) vector containing cDNA encoding ATOH1 (Hath1) delivered via intra-labyrinthine infusion [86]. This study was designed to assess the safety of intra-labyrinthine infusion as well as changes in pure tone audiometry compared to pre-treatment levels over the course of two years. The trial, sponsored by Novartis, was suspended in late 2019 due to an apparent lack of efficacy. The trial only enrolled individuals with profound hearing loss, which may have had an effect on the outcome.

3.5. Challenges in Gene Therapy

Usher gene protein products have been implicated in the development of two key structures in the inner ear—the hair bundles and ribbon synapse [87,88]. While these structures present a clear target for future therapies, hearing loss in USH1 and USH2 is congenital. At the time of birth, the damage has already been done; human hair cells are fully mature with response to sound at 25–27 weeks gestation [89]. In mice, the inner ear is still maturing at birth, and auditory function does not occur until about postnatal day 15. This temporal difference in murine and human inner ear development means that a successful intervention in a mouse model may not directly translate to humans. Applied to humans, post-natal therapy in a mouse model would need to take place in utero, and the implications of these trials are limited unless the therapy is delivered to a mature inner ear [90].

4. Applying Gene Therapy Modalities to Usher-Related Hearing Loss

4.1. Gene Therapy: Gene Modulation and Editing

4.1.1. Antisense Oligonucleotides and RNAi

RNA interference (RNAi) technology uses small RNA molecules to guide the sequence-specific silencing of a target gene by binding to the complementary sequence and inducing mRNA degradation. This approach has been shown to effectively target therapeutically relevant genes, particularly those with variants inherited in an autosomal dominant, gain-of-function manner [91]. The use of RNAi as a therapeutic approach for Usher syndrome will be far more limited since it is an autosomal recessive disease resulting from defective or absent proteins. Antisense oligonucleotides (ASO) are short sequences of RNA/DNA that can bind to complementary RNA strands, inhibiting translation. ASO therapy has been used primarily in mouse models of USH1C, specifically to prevent the transcription of a c.216 G > A mutation which creates an aberrant splice site resulting in a frameshift and premature stop. Various studies have shown both auditory and vestibular rescue (Table 3) [92].
Table 3. Overview of animal-modeled therapies for Usher syndrome in the inner ear.

| Type      | Subtype | Mutation       | Vector/Molecule                  | Delivery Method         | Intervention Time | Hair Cell Penetrance | Auditory Outcome | Vestibular Outcome | Source |
|-----------|---------|----------------|----------------------------------|-------------------------|-------------------|----------------------|-------------------|--------------------|--------|
| Type 1    | USH1C   | c.216 G > A    | AAV2/Anc80L65                    | RWM injection           | P0–P1             | Auditory rescue at low frequencies | Rescued           | Rescued, comparable to WT | Pan [93]|
|           | USH1C   | c.216 G > A    | Antisense oligonucleotide        | Intraperitoneal injection | P3–P5             | Rescued, comparable to WT      | Rescued, comparable to WT | Lentz [94]|
|           | USH1C   | c.216 G > A    | Antisense oligonucleotide        | Intraperitoneal injection | P10               | Partially rescued         | Rescued, comparable to WT | Lentz [94]|
|           | USH1C   | c.216 G > A    | Antisense oligonucleotide        | Amniotic microinjection | E13–E13.5         | Partially rescued          | Rescued, comparable to WT | Lentz [94]|
|           | USH1C   | c.216 G > A    | Antisense oligonucleotide        | Intraperitoneal injection | P5                | Depreux [95]|
|           | USH1G   | Ush1g<sup>−/−</sup> | AAV8                             | RWM injection           | P2.5              | IHC: 87% ± 4% (apex), 45% ± 6% (base) | IHC: 33% ± 6% (apex), 25% ± 5% (base) | Partial restoration | Emptoz [96]|
| Type 2    | USH2D   | Ush2a Whirler  | AAV8-whirlin                     | Posterior semicircular canal injection | P4                | IHC: 77.1% ± 12.7% | OHC: 13.3% ± 9.82% | Most hearing improvement at 8 kHz | Isgrig [97]|
| Type 3    | USH3A   | Clrn1<sup>−/−</sup> | AAV9-PHP.B                       | RWM injection           | P1                | IHC: 60–80% | OHC: 30–40% | Rescued hearing at low frequencies (4–8 kHz) | György [98]|
|           | USH3A   | Clrn1<sup>−/−</sup> Myo15-Cre<sup>−/−</sup> | AAV2/8-Clrn1                    | RWM injection           | P1–P3             | IHC: 90% | OHC: 20% | Restored hearing | Dulon [99]|
|           | USH3A   | Clrn1<sup>−/−</sup> KO TgAC1 | AAV2-Clrn1-UTR AAV8-Clrn1-UTR  | RWM injection           | P1–P3             | Partially restored (20–30 dB shy of WT) | Geng [100]|

Int. J. Mol. Sci. 2021, 22, 3910
6 of 15
4.1.2. Genomic Editing

The CRISPR/Cas9 system emerged in 2013, as a novel technology for genome editing [101]. The technology harnesses the base sequence structure of DNA to make precise changes at selected nucleotides on the genome. CRISPR (clustered regularly interspaced short palindromic repeats) serves as an “adaptive immune” system for bacteria allowing them to recognize and remove pathogenic bacteriophage sequences and prove the integrity of their genomes [102]. CRISPR involves the use of guide RNA sequences which bear complementarity to the target DNA sequence flanked directly by a protospacer-adjacent motifs (PAMs) an essential sequence for the functionality of the CRISPR system [103]. This RNA–DNA base pairing flanked by the PAM sequence defines the CRISPR targeting specificity facilitating the recruitment of the Cas9 endonuclease that induces a double strand DNA break. This double strand break is corrected by the cell through either non-homologous end joining (NHEJ) or homology-directed repair (HDR). The most commonly used Cas9 is derived from *Streptococcus pyogenes* but Cas9 or Cas9-related proteins with variable PAM sequences have been identified in a variety of bacteria and archaea. The fixing of the double strand DNA breaks using non-homologous end joining is an imprecise process that leads to the introduction of insertions and deletion around the cut site. On the other hand, providing a template DNA strand to guide the homology-directed repair allows for the precise repair of the break and provides an opportunity to alter the DNA sequence in a controlled manner (e.g., the introduction of a single nucleotide variant in the DNA sequence). Prior to the advent of CRISPR/Cas9, zinc-finger-nuclease-induced double-stranded breaks was explored as a method of gene repair of an USH1C p.R31 * mutation [104]. Although CRISPR/Cas9-based genome editing has been used extensively in the laboratory, the transition to clinical application is a more difficult undertaking. Fuster-Garcia et al. had some success targeting the c.229delG mutation in fibroblasts from a patient with USH2A with an RNA-Cas9 ribonucleoprotein and homologous recombination repair with an engineered template [105]. The CRISPR/Cas9 has been used in the murine inner ear; Gao et al. demonstrated the successful use of a Cas9-guide RNA complex in a mouse model of autosomal dominant deafness [91]. To date, there have not been inner ear animal models studying the efficacy of gene editing technology in Usher syndrome.

4.2. Gene Therapy: Gene Replacement

4.2.1. Viral Delivery

When selecting a viral vector, many factors must be considered. The vector cargo capacity must be able to accommodate the length of the replacement gene, and the vector must effectively transduce the target cell type within the body. The immunoreactivity of the virus is also an important factor, with an ideal vector eliciting little to no immune response.

4.2.2. Types of Viruses Used in Gene Therapy

Different viral vectors have been explored in the inner ear including adenovirus, adeno-associated virus (AAV), retrovirus, HSV, and lentivirus [106–108]. Since they do not integrate into the host genome, adenovirus vectors are unable to confer long-term expression of the target gene. However, compared to adenoviruses, adeno-associated viruses (AAVs) have emerged as a good candidate vector due to their decreased immune response and ability to confer sustained expression of the gene product in the inner ear [109].

4.2.3. Viral Vectors for the Inner Ear (Anc80L65)

Though immunoreactivity to AAV has been observed to be low, as an endemic virus, prevalence of pre-existing immunity to AAV approaches 50% in some populations [110]. Anc80L65, the ancestor of AAV serotypes 1, 2, 8, and 9, was identified by Zinn et al. through in silico analysis as an ideal candidate due to its ability to circumvent existing immunity to better deliver genes to the inner ear [110]. Furthermore, in a mouse model of USH1C (c.216 G > A), the AAV2/Anc80L65 achieved stabilization of hair cells and bundles, reducing the degeneration and preserving function [93]. The Anc80 virus was found to outperform
all other AAVs in level of expression in inner and outer hair cells in a mouse model with stable expression at one month follow-up. In addition to expression in the cochlea, the virus also showed expression in human vestibular tissue [109].

Other viruses have been explored; a synthetic AAV2.7m8 has been used successfully in the inner ear to target cochlear hair and supporting cells, and AAV9-PHP.B rescued hearing loss in Usher 3A genes (CLRN-1) [98,111]. AAVs in the inner ear are known to more effectively transduce inner hair cells (IHCs) than outer hair cells (OHCs), with AAV2 and AAV8 providing the most effective delivery [112,113]. All animal-modeled therapies for Usher syndrome in the literature are outlined in Table 3.

A vector must accommodate the sequence within its own genome and deliver it to the target tissue. Viral capacity varies; the AAV can carry a transgene of up to 4 kb, while a dual-AAV system can be deployed to deliver larger payloads (6kb) to the inner ear [114]. Usher pathogenic target genes vary in length and location, ranging from 561 base pairs (bp) to 18,918 bp with between three and 90 exons (Table 4).

| Gene     | Total Exons | Base Pairs | Location   |
|----------|-------------|------------|------------|
| MYO7A    | 49          | 86,996     | 11q13.5    |
| USH1C    | 27          | 50,517     | 11p15.1    |
| CDH23    | 70          | 419,028    | 10q22.1    |
| PCDH15   | 38          | 998,461    | 10q21.1    |
| USH1G    | 3           | 7173       | 17q25.1    |
| CIB2     | 6           | 26,840     | 15q25.1    |
| USH2A    | 73          | 800,553    | 1q41       |
| ADGRV1   | 90          | 605,641    | 5q14.3     |
| WHRN     | 12          | 103,394    | 9q32       |
| CLRN1    | 4           | 44,773     | 3q25.1     |

4.2.4. Gene Stabilization

There is minimal research on gene stabilization methods. In USH3A, the CLRN1 c.144T > G, p.Asn48Lys missense mutation results in unstable gene products. A small molecule, BioFocus 844, was identified through successive screenings, and mitigated the progression of USH3A in a Tg;KI/KI mouse model through the stabilization of the dysfunctional protein product [115].

4.2.5. Exon Skipping

Often in a large protein, such as many of the Usher-related proteins, there is only a small mutation that leads to the loss of function of the whole protein. These large proteins also often contain subunit redundancy. It has thus been recognized that there is potential to skip any exons that contain a mutation and still end up with a functional or partially-function protein. Skipping has been carried out by use of small RNAs, antisense oligonucleotides (ASO), and CRISPR. Exon skipping has had some success in addressing diseases such as Duchenne’s muscular dystrophy [116,117], and has potential for use in Usher syndrome.

The deep intronic variant c.7595-2144A > G in USH2A causes a splice donor site in intron 40 which in turn causes the addition of a 152 bp pseudoexon into the transcript. This leads to a premature stop and a non-functional protein [118]. Slijkerman et al. were able to use an ASO to target the pseudoexon and effectively skip it to restore the expression of wild type USH2A in effected fibroblasts [119]. This proved to be an effective option to evaluate clinically for c.7595-2144A > G USH2A mutations, however this is a relatively rare mutation. Additionally, any therapy involving ASOs would require appropriate delivery vehicles and repeat dosing.
The most common USH2A mutation is c.2299delG [120]. Pendse et al. targeted this mutation in a mouse model harboring a mutation in Ush2a exon 12, which is analogous to the human exon 13. They employed CRISPR/Cas9 editing to knock out and skip exon 12 in the mice. The resultant product properly localized in the cochlea and was able to restore hair cell structure and auditory function in the mice [121].

4.3. Delivery Challenges

One obstacle in the progression from molecular therapy to clinical use is efficient delivery of the bioactive molecules to the correct target cells. The complexity of the bony-labyrinthine barrier presents a challenge for drug delivery, but its unique structure also creates opportunity for novel approaches [122]. Previously, the inner ear was believed to be immune privileged due to the lack of lymphatic drainage from the cochlea, though macrophages are now known to migrate into and reside in the cochlea [123]. This may make the cochlea more amenable to viral delivery with reduced potential for immune engagement. The immune response to viral delivery platforms is complex, and it is difficult to determine the long-term safety of transgene expression [122]. Multiple strategies to reduce the immune response to AAV viral vectors have been proposed, including selection of AAV-naive subjects, use of highly efficient AAVs and engineered AAV serotypes, or the administration of immunosuppressant drugs in combination with the viral vector delivery [124].

Physical delivery of these therapeutics also poses its own set of challenges. The cochlea is set in the temporal bone, and as such must be accessed surgically [125]. There are several techniques to deliver these potential therapeutics to the inner ear including round window membrane and oval window membrane injections [126], canalostomy with injection in the posterior semicircular canal [97], and utricle injection [127]. The most common and promising are methods that support the diffusion of therapeutics through the cochlea are round window membrane and oval window membrane injections such as round window injection.

5. Discussion

5.1. From Animal Models to Human Trials

While the majority of in vivo research has been conducted in mouse models, Gyorgy et al. found that AAV9-PHP.B mediated almost complete transduction to OHCs and IHCs in a non-human primate model [98]. Jüttner et al. found that in AAV-targeting glial cells in the retina, the probability of an AAV targeting the same cell class was 0.32, compared to a 0.67 probability between non-human primates and humans. As a result, vectors optimized to target cell types in murine models may not directly translate to human use. The study also noted, however, that the probability of an AAV expressing in a given cell group in humans if it does not express in mice is low, meaning that mice may be a useful model for screening and restricting the number of AAVs to be further tested in humans and non-human primates [128].

Ultimately, progression to clinical trials in humans relies on the translation of animal model results to human physiology. The trail by Gyorgy et al. is the only trial of a gene therapy targeting an Usher etiology that has included a non-human primate [98]. Though there remain numerous cultural and practical barriers to studies in non-human primates, these trials ease the translation from animal models to clinically viable therapy [129].

5.2. Overcoming Vector Capacity

Some Usher-related genes are very large and beyond the capacity of a single viral vector. The carrying capacity of the viral vectors can be overcome through implementing dual and triple recombinant vectors. Akil et al. demonstrated the successful delivery of otoferlin (DFNB9) to the murine inner ear [130]. Dual and triple AAV modalities should be considered for treatment of Usher subtypes with pathogenic genes larger than single AAV capacity of 4.7 kb (MYO7A, PCDH15, ADGRV1, CDH23, and USH2A).
Exon skipping is also a promising method for compensation of loss of function when the whole gene product is too large to be efficiently delivered to the target cells [119,121].

5.3. Prevention vs. Correction

The previously described therapies have been delivered to the developing murine inner ear, as early postnatal mice have inner ears that are still developing. In the current treatment setting, diagnosis in humans is largely made following the development of a fully formed cochlea and dysfunctional hair cells. Therapies deployed before or during development are valuable, but future trials must consider the therapeutic modalities targeting the developed inner ear.

Earlier diagnosis of Usher patients would aid in early intervention. With up to 90% of Usher patients having disease caused by mutations in known USH genes, increasing molecular diagnosis efforts and identifying specific genetic etiologies is an important step in the therapeutic process [131].

5.4. Conclusions

Usher syndrome is the leading cause of deaf-blindness. The genetic etiologies have been extensively studied. Recent progress using gene-based therapies for Usher-related retinitis pigmentosa gives hope that similar techniques can be applied to the inner ear to ameliorate the deleterious effects of Usher mutations on human hearing.

Author Contributions: B.M.C., E.M.J. and X.L. designed and prepared the manuscript. B.L.L., P.-C.T., J.Y., S.H.B. and D.M.D. provided substantial input and feedback during the manuscript preparation. All authors have read and agreed to the published version of the manuscript.

Funding: Liu’s lab is supported by NIH grants R01DC005575, R01DC012115.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Moser, T.; Starr, A. Auditory neuropathy—Neural and synaptic mechanisms. Nat. Rev. Neurol. 2016, 12, 135. [CrossRef] [PubMed]
2. Held, P.; Fellner, C.; Fellner, F.; Seitz, J.; Strutz, J. MRI of inner ear anatomy using 3D MP-RAGE and 3D CISS sequences. Br. J. Radiol. 1997, 70, 465–472. [CrossRef]
3. Yan, D.; Liu, X.Z. Cochlear molecules and hereditary deafness. Front. Biosci. 2008, 13, 4972–4983. [CrossRef]
4. Géloc, G.S.G.; Lennan, G.W.T.; Richardson, G.P.; Kros, C.J. A quantitative comparison of mechanoelectrical transduction in vestibular and auditory hair cells of neonatal mice. Proc. R. Soc. B Biol. Sci. 1997, 264, 611–621. [CrossRef] [PubMed]
5. WHO. Available online: https://www.who.int/health-topics/hearing-loss (accessed on 21 July 2020).
6. Willems, P.J. Genetic Causes of Hearing Loss. N. Engl. J. Med. 2000, 342, 1101–1109. [CrossRef]
7. Marazita, M.L.; Ploughman, L.M.; Rawlings, B.; Remington, E.; Arnos, K.S.; Nance, W.E. Genetic epidemiological studies of early-onset deafness in the U.S. school-age population. Am. J. Med. Genet. 1993, 46, 486–491. [CrossRef] [PubMed]
8. Yan, D.; Kannan-Sundhari, A.; Vishwanath, S.; Qing, J.; Mittal, R.; Kameswaran, M.; Liu, X.Z. The Genetic Basis of Nonsyndromic Hearing Loss in Indian and Pakistani Populations. Genet. Test. Mol. Biomarkers 2015, 19, 512–527. [CrossRef]
9. Mittal, R.; Patel, K.; Mittal, J.; Chan, B.; Yan, D.; Grati, M.; Liu, X.Z. Association of PRPS1 Mutations with Disease Phenotypes. Dis. Markers 2015, 2015, 1–7. [CrossRef] [PubMed]
10. Boudevyins, A.; Ende, J.V.D.; Sommen, M.; Wuyts, W.; Peeters, N.; Van de Heyning, P.; Van Camp, G. Role of Targeted Next Generation Sequencing in the Etiological Work-Up of Congenitally Deaf Children. Otol. Neurotol. 2018, 39, 732–738. [CrossRef] [PubMed]
11. Morton, N.E. Genetic linkage and complex diseases: A comment. Genet. Epidemiol. 1990, 7, 33–34. [CrossRef] [PubMed]
12. Angeli, S.; Lin, X.; Liu, X.Z. Genetics of Hearing and Deafness. Anat. Rec. Adv. Integr. Anat. Evol. Biol. 2012, 295, 1812–1829. [CrossRef] [PubMed]
13. Carpena, N.T.; Lee, M.Y. Genetic Hearing Loss and Gene Therapy. Genom. Inform. 2018, 16, e20. [CrossRef] [PubMed]
14. Müller, U.; Barr-Gillespie, P.G. New treatment options for hearing loss. Nat. Rev. Drug Discov. 2015, 14, 346–365. [CrossRef] [PubMed]
15. Géloc, G.S.G.; Holt, J.R. Sound Strategies for Hearing Restoration. Science 2014, 344, 1241062. [CrossRef] [PubMed]
16. HHL (Hereditary Hearing Loss). Hereditary Hearing Loss Homepage. Available online: http://hereditaryhearingloss.org/main.aspx?c=HHH&amp;n=86162 (accessed on 30 January 2021).
17. Vernon, M. Usher’s syndrome-deafness and progressive blindness. Clinical cases, prevention, theory and literature survey. J. Chronic Dis. 1969, 22, 133–151. [CrossRef]
18. Géliec, G.G.; El-Amraoui, A. Disease mechanisms and gene therapy for Usher syndrome. Hear. Res. 2020, 394, 107932. [CrossRef]
19. Young, N.M.; Johnson, J.; Mels, M.B.; Hain, T.C. Cochlear implants in young children with Usher’s syndrome. Ann. Otol. Rhinol. Laryngol. 1995, 104 (Suppl. 2), 342–345. [CrossRef]
20. Mathur, P.; Yang, J. Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities. Biochim. Et Biophys. Acta Mol. Basis Dis. 2015, 1852, 406–420. [CrossRef]
21. Reiners, J.; Nagel-Wolfrum, K.; Jürgens, K.; Märker, T.; Wolfrum, U. Molecular basis of human Usher syndrome: Deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp. Eye Res. 2006, 83, 97–119. [CrossRef]
22. Fakin, A.; Jarc-Vidmar, M.; Glavač, D.; Bonnet, C.; Petit, C.; Hawlina, M. Fundus autofluorescence and optical coherence tomography in relation to visual function in Usher syndrome type 1 and 2. Vis. Res. 2012, 75, 60–70. [CrossRef]
23. Loundon, N.; Marlin, S.; Busquet, D.; Denoyelle, F.; Roger, G.; Renaud, F.; Garabedian, E.N. Usher Syndrome and Cochlear Implantation. Otol. Neurotol. 2003, 24, 216–221. [CrossRef]
24. El-Amraoui, A.; Petit, C. The retinal phenotype of Usher syndrome: Pathophysiological insights from animal models. Comptes Rendus Biol. 2014, 337, 167–177. [CrossRef] [PubMed]
25. Toms, M.; Bitner-Glindzicz, M.; Webster, A.; Moosajee, M. Usher syndrome: A review of the clinical phenotype, genes and therapeutic strategies. Expert Rev. Ophthalmol. 2015, 10, 241–256. [CrossRef]
26. Abadie, C.; Blanchet, C.; Baux, D.; Larrieu, L.; Besnard, T.; Ravel, P.; Biboulet, R.; Hamel, C.; Malcolm, S.; Mondain, M.; et al. Audiological findings in 100 USH2 patients. Clin. Genet. 2011, 82, 433–438. [CrossRef] [PubMed]
27. Millán, J.M.; Aller, E.; Jaijo, T.; Blanco-Kelly, F.; Gimenez-Pardo, A.; Ayuso, C. An Update on the Genetics of Usher Syndrome. J. Ophthalmol. 2011, 2011, 1–8. [CrossRef]
28. Fishman, G.A.; Bobzeyoglu, S.; Massof, R.W.; Kimberling, W. Natural course of visual field loss in patients with type 2 Usher syndrome. Retina 2007, 27, 601–608. [CrossRef]
29. Spandau, U.H.; Rohrschneider, K. Prevalence and geographical distribution of Usher syndrome in Germany. Graefe’s Arch. Clin. Exp. Ophthalmol. 2002, 240, 495–498. [CrossRef]
30. Cohen, M.; Bitner-Glindzicz, M.; Luxon, L. The changing face of Usher syndrome: Clinical implications. Int. J. Audiol. 2007, 46, 82–93. [CrossRef] [PubMed]
31. Jouret, G.; Poirier, C.; Spodenkiewicz, M.; Jaquin, C.; Gouy, E.; Arndt, C.; Labrousse, M.; Gaillard, D.; Doco-Fenzy, M.; Lebre, A.-S. Genetics of Usher Syndrome: New Insights from a Meta-analysis. Otol. Neurotol. 2019, 40, 121–129. [CrossRef]
32. Kimberling, W.J.; Hildebrand, M.S.; Shearer, A.E.; Jensen, M.L.; Halder, J.A.; Trzupek, K.; Cohn, E.S.; Weleber, R.G.; Stone, E.M.; Smith, R.J.H. Frequency of Usher syndrome in two pediatric populations: Implications for genetic screening of deaf and hard of hearing children. Genet. Med. 2010, 12, 512–516. [CrossRef]
33. Boughmann, J.; Vernon, M.; Shaver, K. Usher syndrome: Definition and estimate of prevalence from two high-risk populations. J. Chronic Dis. 1983, 36, 595–603. [CrossRef]
34. Chaib, H.; Kaplan, J.; Gerber, S.; Vincent, C.; Ayadi, H.; Slim, R.; Munnich, A.; Weissenbach, J.; Petit, C. A newly identified locus for Usher syndrome type I, USH1E, maps to chromosome 21q21. Hum. Mol. Genet. 1997, 6, 27–31. [CrossRef]
35. Ahmed, Z.M.; Riazuddin, S.; Khan, S.N.; Friedman, P.L.; Friedman, T.B. USH1H, a novel locus for type I Usher syndrome, maps to chromosome 15q22-23. Clin. Genet. 2007, 75, 86–91. [CrossRef]
36. Jaworek, T.J.; Bhatti, R.; Latief, N.; Khan, S.N.; Riazuddin, S.; Ahmed, Z.M. USH1K, a novel locus for type I Usher syndrome, maps to chromosome 10p11.21–q21.1. J. Hum. Genet. 2012, 57, 633–637. [CrossRef] [PubMed]
37. Hmaní, M.; Ghorbel, A.; Bouilla-Elaiaed, A.; Ben Zina, Z.; Kammoun, W.; Drira, M.; Chaabouni, M.; Petit, C.; Ayadi, H. A novel locus for Usher syndrome type II, USH2B, maps to chromosome 3 at p23–24.2. Eur. J. Hum. Genet. 1999, 7, 363–367. [CrossRef] [PubMed]
38. Liu, X.-Z.; Walsh, J.; Mburu, P.; Kendrick-Jones, J.; Cope, M.J.T.; Steel, K.P.; Brown, S.D. Mutations in the myosin VIIA gene cause non-syndromic recessive deafness. Nat. Genet. 1997, 16, 188–190. [CrossRef]
39. Jacobson, S.G.; Cideciyan, A.V.; Aleman, T.S.; Sumaroka, A.; Roman, A.J.; Gardner, L.M.; Prosser, H.M.; Mishra, M.; Bech-Hansen, N.T.; Herrera, W.; et al. Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism. Hum. Mol. Genet. 2008, 17, 2405–2415. [CrossRef] [PubMed]
40. Weil, D.; Küssel, P.; Blanchard, S.; Levy, G.G.; Levi-Acobas, F.; Drira, M.; Ayadi, H.; Petit, C. The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA gene. Nat. Genet. 1997, 16, 191–193. [CrossRef] [PubMed]
41. Ouyang, X.; Xia, X.; Verpy, E.; Du, L.; Pandya, A.; Petit, C.; Balkany, T.; Nance, W.E.; Liu, X. Mutations in the alternatively spliced exons of USH1C cause non-syndromic deafness. Qual. Life Res. 2002, 111, 26–30. [CrossRef]
42. Ahmed, Z.M.; Smith, T.N.; Riazuddin, S.; Makishima, T.; Ghosh, M.; Bokhari, S.; Menon, P.S.; Deshmukh, D.; Griffith, A.J.; Riazuddin, S.; et al. Nonsyndromic recessive deafness DFNB18 and Usher syndrome type IC are allelic mutations of USHIC. Qual. Life Res. 2002, 110, 527–531. [CrossRef]
43. Lentz, J.; Savas, S.; Ng, S.-S.; Athas, G.; Deininger, P.; Keats, B. The USH1C 216G? A splice-site mutation results in a 35-base-pair deletion. Qual. Life Res. 2004, 116, 225–227. [CrossRef]
44. Bolz, H.; Von Brederlow, B.; Ramírez, A.; Bryda, E.C.; Kutsche, K.; Nothwang, H.G.; Seeliger, M.; Cabrera, M.D.C.-S.; Vila, M.C.; Molina, O.P.; et al. Mutations of the CDH23 gene encoding a new member of the cadherin gene family cause Usher syndrome type 1D. *Nat. Genet.* 2001, 27, 108–112. [CrossRef] [PubMed]

45. Bork, J.M.; Peters, L.M.; Riazuddin, S.; Bernstein, S.L.; Ahmed, Z.M.; Ness, S.L.; Polomono, R.; Ramesh, A.; Schloss, M.; Srisailapathy, C.R.S.; et al. Usher Syndrome 1D and Nonsyndromic Autosomal Recessive Deafness DFNB12 Are Caused by Allelic Mutations of the Novel Cadherin-Like Gene CDH23. *Am. J. Hum. Genet.* 2001, 68, 26–37. [CrossRef] [PubMed]

46. Ahmed, Z.M.; Riazuddin, S.; Bernstein, S.L.; Ahmed, Z.; Khan, S.; Griffith, A.J.; Morell, R.J.; Friedman, T.B.; Riazuddin, S.; Wilcox, E.R. Mutations of the Protocadherin Gene PCDH15 Cause Usher Syndrome Type 1F. *Am. J. Hum. Genet.* 2003, 69, 25–34. [CrossRef]

47. Ahmed, Z.M.; Riazuddin, S.; Aye, S.; Ali, R.A.; Verselaar, H.; Anwar, S.; Belyantseva, P.P.; Qasim, M.; Riazuddin, S.; Friedman, T.B. Gene structure and mutant alleles of PCDH15: Nonsyndromic deafness DFNB23 and type 1 Usher syndrome. *Qual. Life Res.* 2008, 124, 215–223. [CrossRef]

48. Pepermans, E.; Michel, V.; Goodyear, R.; Bonnet, C.; Abdi, S.; Dupont, T.; Gherbi, S.; Holder, M.; Makrelouf, M.; Hardelin, J.; et al. The CD2 isoform of protocadherin-15 is an essential component of the link-sink complex in mature auditory hair cells. *EMBO Mol. Med.* 2014, 6, 984–992. [CrossRef]

49. Weil, D.; El-Amraoui, A.; Masmoudi, S.; Mustapha, M.; Kikkawa, Y.; Lainé, S.; Delmaghani, S.; Adato, A.; Nadifi, S.; Zina, Z.B.; et al. Usher syndrome type 1G (USH1G) is caused by mutations in the gene encoding SANS, a protein that associates with the USH1C protein, harmonin. *Hum. Mol. Genet.* 2003, 12, 463–471. [CrossRef] [PubMed]

50. Booth, K.; Kahrizi, K.; Babanejad, M.; Daghagh, H.; Bademci, G.; Arzhangi, S.; Zareabdollahi, D.; Duman, D.; El-Amraoui, A.; Tekin, M.; et al. Variants in CIB2 cause DFNB48 and not USH1I. *Clin. Genet.* 2018, 93, 812–821. [CrossRef] [PubMed]

51. Michel, V.; Booth, K.T.; Patni, P.; Cortese, M.; Azaiez, H.; Bahlou, A.; Kahrizi, K.; Lambé, M.; Empotoz, A.; Lelli, A.; et al. CIB2, defective in isolated deafness, is key for auditory hair cell mechanotransduction and survival. *EMBO Mol. Med.* 2017, 9, 1711–1731. [CrossRef] [PubMed]

52. Riazuddin, S.; Belyantseva, P.P.; Vreugde, S.; Joensuu, T.; Avidan, N.; Hamalainen, R.H.; Belenkiy, O.; Olender, T.; Bonne-Tamir, B.; Ben-Asher, E.; et al. USH1A gene clarin-1 is essential for hair cell function and associated neural activation. *Hum. Mol. Genet.* 2016, 25, 3910–3922. [CrossRef] [PubMed]

53. Giese, A.P.J.; Tang, Y.Q.; Sinha, G.P.; Bowl, M.R.; Goldring, A.C.; Parker, A.; Freeman, M.J.; Brown, S.D.M.; Riazuddin, S.; Ahmed, Z.M.; et al. Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1I and nonsyndromic deafness DFNB48. *Nat. Genet.* 2012, 44, 1265–1271. [CrossRef] [PubMed]

54. Giese, A.P.J.; Delprat, B.; Michel, V.; Michalski, N.; Chardenoux, S.; Weil, D.; El-Amraoui, A.; Petit, C.; Usherin, the deaf protein in Usher syndrome type II A, is likely to be a component of interstereocilia ankle links in the inner ear sensory cells. *Hum. Mol. Genet.* 2005, 14, 3921–3932. [CrossRef]

55. Mathur, P.D.; Yang, J. Usher syndrome and nonsyndromic deafness: Functions of different whirlin isoforms in the cochlea, vestibular organs, and retina. *Hear. Res.* 2019, 375, 14–24. [CrossRef] [PubMed]

56. Weston, M.D.; Luijendijk, M.W.J.; Humphrey, K.D.; Möller, C.; Kimberling, W.J. Mutations in the VLGRI Gene Implicate G-Protein Signaling in the Pathogenesis of Usher Syndrome Type II. *Am. J. Hum. Genet.* 2004, 74, 357–366. [CrossRef] [PubMed]

57. Ebermann, I.; Lefèvre, G.; Delprat, B.; Michel, V.; Michalski, N.; Chardenoux, S.; Weil, D.; El-Amraoui, A.; Petit, C. Usherin, the deaf protein in Usher syndrome type II A, is likely to be a component of interstereocilia ankle links in the inner ear sensory cells. *Hum. Mol. Genet.* 2005, 14, 3921–3932. [CrossRef]

58. Mathur, P.D.; Yang, J. Usher syndrome and nonsyndromic deafness: Functions of different whirlin isoforms in the cochlea, vestibular organs, and retina. *Hear. Res.* 2019, 375, 14–24. [CrossRef] [PubMed]

59. Mburu, P.; Mustapha, M.; Varela, A.; Weil, D.; El-Amraoui, A.; Holme, R.H.; Rump, A.; Hardisty, R.E.; Blanchard, S.; Coimbra, R.S.; et al. Defects in whirlin, a PDZ domain molecule involved in stereocilia elongation, cause deafness in the whirlin mouse and families with DFNB31. *Nat. Genet.* 2003, 34, 421–428. [CrossRef]

60. Geng, R.; Geller, S.F.; Hayashi, T.; Ray, C.A.; Reh, T.A.; Bermingham-McDonogh, O.; Jones, S.M.; Wright, C.G.; Melki, S.; Imanishi, Y.; et al. Usher syndrome IIIA gene clarin-1 is essential for hair cell function and associated neural activation. *Hum. Mol. Genet.* 2009, 18, 2748–2760. [CrossRef]

61. Adato, A.; Vreugde, S.; Joensuu, T.; Avidan, N.; Hamalainen, R.H.; Belenkiy, O.; Olender, T.; Bonne-Tamir, B.; Ben-Asher, E.; Espinos, C.; et al. USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. *Eur. J. Hum. Genet.* 2002, 10, 339–350. [CrossRef]

62. Gopal, S.R.; Chen, D.H.C.; Chou, S.W.; Zhang, J.; Neuhaus, S.C.F.; Stepanyan, R.; McDermott, B.M., Jr; Alagaram, K.N. Zebrafish models for the mechanosensory hair cell dysfunction in usher syndrome 3 reveal that Clarin-1 is an essential hair bundle protein. *J. Neurosci.* 2015, 35, 10188–10201. [CrossRef]

63. Puffenberger, E.G.; Jinks, R.N.; Sougnez, C.; Cibulskis, K.; Willert, R.A.; Achilly, N.P.; Cassidy, R.P.; Fiorentini, C.J.; Heiken, K.F.; Lawrence, J.J.; et al. Genetic Mapping and Exome Sequencing Identify Variants Associated with Five Novel Diseases (Exome Sequencing and Rare Monogenic Diseases). *PLoS ONE* 2012, 7, e28936. [CrossRef] [PubMed]

64. Ebermann, I.; Lopez, I.; Bitner-Glindzicz, M.; Brown, C.; Koenekoop, R.K.; Bolz, H.J. Deafblindness in French Canadians from Quebec: A predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population. *Genome Biol.* 2007, 8, R47. [CrossRef]
Bonnet, C.; Grati, M.; Marlin, S.; Levilliers, J.; Hardelin, J.-P.; Parodi, M.; Niasme-Grare, M.; Zelenika, D.; D79. Vivero, R.J.; Fan, K.; Angeli, S.; Balkany, T.J.; Liu, X.Z. Cochlear implantation in common forms of genetic deafness.

van Wijk, E.; van der Zwaag, B.; Zimmermann, U.; te Brinke, H.; Kersten, F.F.J.; Märker, T.; Aller, E.; Hoefsloot, L.H.; 87. Cosgrove, D.; Zallocchi, M. Usher protein functions in hair cells and photoreceptors.

Novartis. Safety, Tolerability and Efficacy for CGF166 in Patients with Unilateral or Bilateral Severe-to-profound Hearing Loss—Full Text View—ClinicalTrials.gov. 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT01505062 (accessed on 20 January 2021).

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene. Available online: https://adisinsight.springer.com/trials/700293079 (accessed on 20 January 2021).

Ben-Rebeh, I.; Grati, M.; Bonnet, C.; Bouassida, W.; Hadjamor, I.; Ayadi, H.; Ghorbel, A.; Petit, C.; Masmoudi, S. Genetic analysis of Tunisian families with Usher syndrome type 1: Toward improving early molecular diagnosis. Orphanet J. Rare Dis. 2011, 6, 91. [CrossRef] [PubMed]

Sanofi. Study of SAR421869 in Participants with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT01505062 (accessed on 20 January 2021).

Therapeutics, P. Study to Evaluate Safety and Tolerability of QR-421a in Subjects with RP Due to Mutations in Exon 13 of the USH2A Gene—Full Text View—ClinicalTrials.gov. 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT03780257 (accessed on 20 January 2021).

Zallocchi, M.; Binley, K.; Lad, Y.; Ellis, S.; Widdowson, P.; Iqball, S.; Scripps, V.; Kelleher, M.; Loader, J.; Miskin, J.; et al. EIAV-Based Retinal Gene Therapy in the shaker1 Mouse Model for Usher Syndrome Type 1B: Development of UshStat. PLoS ONE 2014, 9, e94272. [CrossRef] [PubMed]

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene. Available online: https://adisinsight.springer.com/trials/700293079 (accessed on 20 January 2021).

Novartis. Safety, Tolerability and Efficacy for CGF166 in Patients with Unilateral or Bilateral Severe-to-profound Hearing Loss—Full Text View—ClinicalTrials.gov. 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT02132130 (accessed on 20 January 2021).

Cosgrove, D.; Zallocchi, M. Usher protein functions in hair cells and photoreceptors. Int. J. Biochem. Cell Biol. 2014, 46, 80–89. [CrossRef] [PubMed]

Gregory, F.D.; Bryan, K.E.; Panagrič, T.; Calin-Jageman, I.E.; Moser, T.; Lee, A. Harmonin inhibits presynaptic Cav1.3 Ca2+ channels in mouse inner hair cells. Nat. Neurosci. 2011, 14, 1109–1111. [CrossRef] [PubMed]
114. Reisinger, E. Dual-AAV delivery of large gene sequences to the inner ear. Hear. Res. 2020, 394, 107857. [CrossRef] [PubMed]
115. Alagramam, K.N.; Gopal, S.R.; Geng, R.; Chen, D.H.C.; Nemet, I.; Lee, R.; Tian, G.; Miyagi, M.; Malagù, K.F.; Lock, C.J.; et al. A small molecule mitigates hearing loss in a mouse model of Usher syndrome III. Nat. Chem. Biol. 2016, 12, 444–451. [CrossRef]
116. Goyenvalle, A.; Vulin, A.; Fougerousse, F.; Leturcq, F.; Kaplan, J.-C.; Garcia, L.; Danos, O. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004, 306, 1796–1799. [CrossRef]
117. Pramono, Z.A.; Takeshima, Y.; Alimsardjono, H.; Ishii, A.; Takeda, S.; Matsuo, M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 1996, 226, 445–449. [CrossRef]
118. Vaché, C.; Besnard, T.; Le Berre, P.; García-García, G.; Baux, D.; Larrieu, L.; Abadie, C.; Blanchet, C.; Bolz, H.J.; Millan, J.; et al. Usher syndrome type 2 caused by activation of an USH2A pseudoexon: Implications for diagnosis and therapy. Hum. Mutat. 2011, 33, 104–108. [CrossRef]
119. Slijkerman, R.W.; Vaché, C.; Dona, M.; García-García, G.; Claustres, M.; Héterschijt, L.; Peters, T.A.; Hartel, B.P.; Pennings, R.J.; Millan, J.M.; et al. Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation. Mol. Ther. Nucleic Acids 2016, 5, e381. [CrossRef] [PubMed]
120. Aller, E.; Larrieu, L.; Jaijo, T.; Baux, D.; Espinós, C.; González-Candelas, F.; Nájera, C.; Palau, F.; Claustres, M.; Roux, A.-F.; et al. The USH2A c.2299delG mutation: Dating its common origin in a Southern European population. Eur. J. Hum. Genet. 2010, 18, 788–793. [CrossRef] [PubMed]
121. Pendse, N.D.; Lamas, V.; Pawlyk, B.S.; Maeder, M.L.; Chen, Z.-Y.; Pierce, E.A.; Liu, Q. In Vivo Assessment of Potential Therapeutic Approaches for USH2A-Associated Retinal Degeneration. Adv. Exp. Med. Biol. 2019, 1185, 91–96. [CrossRef]
122. Ren, Y.; Landegger, L.D.; Stankovic, K.M. Gene Therapy for Human Sensorineural Hearing Loss. Front. Cell. Neurosci. 2019, 13, 323. [CrossRef] [PubMed]
123. Okano, T. Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss. Front. Pharmacol. 2014, 5, 205. [CrossRef] [PubMed]
124. Mingozzi, F.; High, K.A. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 2013, 122, 23–36. [CrossRef] [PubMed]
125. Kessler, B.W.; Hashisaki, G.T.; Holt, J.R. Gene Transfer in Human Vestibular Epithelia and the Prospects for Inner Ear Gene Therapy. Laryngoscope 2008, 118, 821–831. [CrossRef] [PubMed]
126. Jero, J.; Mhatre, A.N.; Tseng, C.J.; Stern, R.E.; Coling, D.E.; Goldstein, J.A.; Hong, K.; Zheng, W.W.; Hoque, A.S.; Lalwani, A.K. Cochlear Gene Delivery through an Intact Round Window Membrane in Mouse. Hum. Gene Ther. 2001, 12, 539–548. [CrossRef]
127. Lee, J.; Nist-Lund, C.; Solanes, P.; Goldberg, H.; Wu, J.; Pan, B.; Schneider, B.L.; Holt, J.R. Efficient viral transduction in mouse inner ear hair cells with utricle injection and AAV9-PHP.B. Hear. Res. 2020, 394, 107882. [CrossRef]
128. Jüttner, J.; Szabo, A.; Gross-Scherf, B.; Morikawa, R.K.; Rompani, S.B.; Hantz, P.; Szikra, T.; Esposti, F.; Cowan, C.S.; Bhar-rike, A.; et al. Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. Nat. Neurosci. 2019, 22, 1345–1356. [CrossRef] [PubMed]
129. Prescott, M.J.; Langermans, J.A.; Ragan, I. Applying the 3Rs to non-human primate research: Barriers and solutions. Drug Discov. Today. Dis. Model. 2017, 23, 51–56. [CrossRef] [PubMed]
130. Akil, O.; Dyka, F.; Calvet, C.; Empoto, A.; Lahloul, G.; Nouaille, S.; De Monvel, J.B.; Hardelin, J.-P.; Hauswirth, W.W.; Avan, P.; et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc. Natl. Acad. Sci. USA 2019, 116, 4496–4501. [CrossRef]
131. Jiang, L.; Liang, X.; Li, Y.; Wang, J.; Zaneveld, J.E.; Wang, H.; Xu, S.; Wang, K.; Wang, B.; Chen, R.; et al. Comprehensive molecular diagnosis of 67 Chinese Usher syndrome probands: High rate of ethnicity specific mutations in Chinese USH patients. Orphanet J. Rare Dis. 2015, 10, 110. [CrossRef] [PubMed]